dewophile,
From the CC:
Operator
Our next question comes from Avik Roy of Monness, Crespi, Hardt.
Avik Roy – Monness, Crespi, Hardt
Could you review for us your game plan should Teva be able to launch the Low Volume or some other formulation Copaxone before you are able to get on the market and assuming they are able to switch everyone, how easy is it for you to amend your filing or modify your strategy to accommodate that.
Craig Wheeler
So, I can't give you a specific strategy, I can tell you that we have thought very deeply about it both with the original product that we would be able to get approved and launch in any event as well as how we will respond to 0.5 and so we have thought about it quite carefully, we do think that there are multiple opportunities to create value even in a scenario where they are able to switch the entire market which we think is going to be unlikely at this point. But I think we are quite prepared when it comes to our strategy probably we will think about it.
Avik Roy – Monness, Crespi, Hardt
Would it require a completely new file or would you be able to modify your existing filing to accomplish this
Craig Wheeler
That is not something I would like to telegraph. (while laughing)
Avik Roy – Monness, Crespi, Hardt
Fair enough, thanks guys.
Craig Wheeler
Yes, absolutely thanks.
AI
